Chow-White Peter, Ha Dung, Laskin Janessa
Simon Fraser University, Burnaby, Canada.
British Columbia Cancer Agency, Vancouver, Canada.
Hum Resour Health. 2017 Jun 27;15(1):42. doi: 10.1186/s12960-017-0218-z.
It has been over a decade since the completion of the Human Genome Project (HGP), genomic sequencing technologies have yet to become parts of standard of care in Canada. This study investigates medical oncologists' (MOs) genomic literacy and their experiences based on their participation in a cancer genomics trial in British Columbia, Canada.
The authors conducted a survey of MOs from British Columbia, Canada (n = 31, 52.5% response rate), who are actively involved in a clinical genomics trial called Personalized Onco-Genomics (POG). The authors also measured MOs' level of genomic knowledge and attitudes about clinical genomics in cancer medicine.
The findings show a low to moderate level of genomic literacy among MOs. MOs located outside the Vancouver area (the major urban center) reported less knowledge about new genetics technologies compared to those located in the major metropolitan area (26.7 vs 73.3%, P < 0.07, Fisher exact test). Forty-two percent of all MOs thought medical training programs do not offer enough genomic training. The majority of the respondents thought genomics will have major impact on drug discovery (67.7%), and treatment selection (58%) in the next 5 years. They also thought the major challenges are cost (61.3%), patient genomic literacy (48.3%), and clinical utility of genomics (42%).
The data suggest a high need to increase genomic literacy among MOs and other doctors in medical school training programs and beyond, especially to physicians in regional areas who may need more educational interventions. Initiatives like POG play a critical role in the education of MOs and the integration of big data clinical genomics into cancer care.
人类基因组计划(HGP)完成至今已有十多年,但基因组测序技术尚未成为加拿大医疗护理标准的一部分。本研究基于加拿大不列颠哥伦比亚省参与癌症基因组试验的医学肿瘤学家(MOs),调查他们的基因组知识水平及其经历。
作者对来自加拿大不列颠哥伦比亚省的医学肿瘤学家(n = 31,回复率52.5%)进行了一项调查,这些医学肿瘤学家积极参与一项名为个性化肿瘤基因组学(POG)的临床基因组试验。作者还测量了医学肿瘤学家的基因组知识水平以及他们对癌症医学中临床基因组学的态度。
研究结果显示医学肿瘤学家的基因组知识水平处于中低水平。与位于主要大都市地区的医学肿瘤学家相比,位于温哥华地区(主要城市中心)以外的医学肿瘤学家对新基因技术的了解较少(26.7%对73.3%,P < 0.07,Fisher精确检验)。42%的医学肿瘤学家认为医学培训项目提供的基因组培训不足。大多数受访者认为基因组学将在未来5年内对药物研发(67.7%)和治疗选择(58%)产生重大影响。他们还认为主要挑战是成本(61.3%)、患者的基因组知识水平(48.3%)以及基因组学的临床应用价值(42%)。
数据表明,迫切需要提高医学院培训项目及其他机构中医学肿瘤学家和其他医生的基因组知识水平,特别是对可能需要更多教育干预的偏远地区的医生。像POG这样的项目在医学肿瘤学家的教育以及将大数据临床基因组学整合到癌症护理中发挥着关键作用。